Journal of oral biology and craniofacial research · 2021
COVID-19 associated mucormycosis: Staging and management recommendations (Report of a multi-disciplinary expert committee).
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Malhotra Hardeep Singh, Gupta Prashant, Mehrotra Divya, Dandu Himanshu, Kohli Neera, Verma Veerendra, Kaur Apjit, Kumar Neeraj, Prabhu Vikas, Singh Manish Kumar, Jaiswal Riddhi, Mishra Brijesh, Ojha Bal Krishna, Bhardwaj Nitin Dutt, Atam Virendra, Puri Bipin
Аннотация
Even before the onslaught of COVID-19 pandemic could settle, the unprecedented rise in cases with COVID-19 associated mucormycosis pushed the medical health to the fringe. Hyperglycaemia and corticosteroids appear to be the most consistent associations leading to the commonest manifestation of mucormycosis, Rhino-Orbito-Cerebral Mucormycosis. To address challenges right from categorisation and staging of the disease to the management of relentless progression, a multi-disciplinary expert committee was formed to handle the task in an evidence-based format to enforce best practices. The report of the committee on one hand attempts to succinctly present the currently available evidence while at the other also attempts to bridge the evidence-deficient gaps with the specialty-specific virtuosity of experts.